•  02122264144
  •  info[@]payvandlab.com
  • تهران - خيابان شريعتی – خيابان وحيد دستگردی (ظفر)- نرسيده به خيابان نفت پلاك 174

T ProLymphocytic Leukemia panel at diagnosis ( 16-18 CD markers)

T(1:13) or PAX7-FKHR for Rhabdomyo sarcoma

t(1;13) PAX7/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma

t(1;13) PAX7/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma RT- PCR

 t(1;14) SIL-TAL or del(1)SIL-TAL1 for T-ALL

t(1;19)TCF3-PBX1 or E2A-PBX1 /t(1;19)

t(11;14) IgH/CCND1 for Mantle cell Lymphoma

t(11;14) IgH/CCND1 or Cyclin D1/BCL1 /t(11;14) for Mantle cell lymphoma

t(11;14)(q13;q32) IGH/CCND1 for Mantle Cell Lymphoma  (MCL)

t(11;18) API2/MLT for MALT Lymphoma

t(12;21) ETV6-RUNX1 or TEL-AML1 / t(12;21) for ALL (Qualitative)

t(12;21) ETV6-RUNX1 or TEL-AML1 / t(12;21) for ALL (Quantitative)

t(14;18) IgH/BCL2 (MBR) for Follicular Lymphoma

t(14;18) IgH/BCL2 (MBR) or IgH/BCL2 / t(14;18) for Follicular lymphoma

t(14;18) IgH/BCL2 (mcr) for Follicular Lymphoma

t(14;18) IgH/BCL2 (mcr) or IgH/BCL2 / t(14;18) for Follicular lymphoma

t(15;17) PML-RARA for AML-M3 and M3v  (Quantitative)

t(15;17) PML-RARA for AML-M3 and M3v (Qualitative)

T(2:13) or PAX3-FKHR for Rhabdomyo sarcoma

t(2;13) PAX3/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma

t(2;13) PAX3/FOXO1A (FKHR) for Alveolar Rhabdomyosarcoma

t(4;11) MLL-AF4 for ALL

t(8;14) IgH/c-Myc for Burkitt Lymphoma / ALL- L3

t(8;14)IgH/c-Myc & t(8;22) IgL/c-Myc & t(2;8) IgK/c-Myc for Burkitt Lymphoma -FISH

t(8;21)(q22;q22.1);RUNX1-RUNX1T1 or AML1-ETO/t(8;21)

T-ALL Body fluid panel ( 3-5 CD markers)

T-cell LGL Leukemia panel at diagnosis ( 16-18 CD markers)

TCR-γ (Gamma) gene rearrangement  B ( Clonality Assay)

TCR-γ (Gamma) gene rearrangement A (Clonality Assay)

TCR-γ gene  rearrangement for NHL

TCR-δ (Delta) gene rearrangement (Clonality Assay)

Thin prep

Thiopurine Meyhyl Transferase (TPMT) Toxicity to Azathioprin, 6 Mercaptopurine, 6 thioguanine

Toxoplasma gondii

Treponema pallidum

نوشتن دیدگاه

تصویر امنیتی
تصویر امنیتی جدید

Powered by Amazing-Templates.com 2014 - All Rights Reserved.